...
首页> 外文期刊>Tumour biology : >Revisiting the role of MCL1 in tumorigenesis of solid cancer: gene expression correlates with antiproliferative phenotype in breast cancer cells and its functional regulatory variants are associated with reduced cancer susceptibility.
【24h】

Revisiting the role of MCL1 in tumorigenesis of solid cancer: gene expression correlates with antiproliferative phenotype in breast cancer cells and its functional regulatory variants are associated with reduced cancer susceptibility.

机译:再次探讨MCL1在实体癌发生中的作用:基因表达与乳腺癌细胞的抗增殖表型相关,其功能调控变异体与降低的癌症易感性有关。

获取原文
获取原文并翻译 | 示例
           

摘要

Compared to the well-defined anti-apoptotic role of myeloid cell leukemia sequence 1 (MCL1), its antiproliferative function in tumorigenesis is less studied. We had recently reported that regulatory variants of MCL1 contribute to enhanced promoter activity but reduced risk of lung cancer. We hypothesized that MCL1 expression may manifest antiproliferative phenotype and its functional variations may have etiological relevance for breast cancer. We manipulated MCL1 expression in MCF-7 cells and MDA231 with overexpression and knockdown, analyzed the effects on cell viability and cell cycling phase, and characterized the correlation with expression profiles of key regulators of cell cycle. We further genotyped the -190 insertion polymorphism and the neighboring single nucleotide polymorphisms (SNPs) in 745 breast cancer patients and 537 controls and analyzed their association with cancer risk. We confirmed that heightened expression of MCL1 resulted in decreased proliferation ability of breast cancer cells. We further observed that MCL1 overexpression in breast cancer cells resulted in cell cycle progression arresting in S phase and concomitant enhanced expression of p27, which could be rescued by p27 knockdown with co-transfection of small interfering RNA (siRNA). Furthermore, we found a significant reduction in breast cancer risk [odds ratio (OR)?=?0.74; 95 % confidence interval (CI)?=?0.59-0.93] associated with -190 insertion genotype; the expression-enhancing regulatory haplotype (OR 0.79; 95 % CI 0.66-0.95) and diplotype (OR 0.71; 95 % CI 0.57-0.89) were consistently associated with decreased cancer susceptibility. The study demonstrates that the expression-enhancing regulatory variants of MCL1 are protective modifiers of breast cancer risk, and reduced cell proliferation and arrested cell cycle progression partly mediated by p27 might be the underlying mechanism.
机译:与明确定义的髓样细胞白血病序列1(MCL1)的抗凋亡作用相比,在肿瘤发生中其抗增殖功能的研究较少。我们最近报道了MCL1的调控变异体有助于增强启动子活性,但降低了患肺癌的风险。我们假设MCL1表达可能表现出抗增殖表型,其功能变异可能与乳腺癌的病因相关。我们通过过度表达和敲低来操纵MCF-7细胞和MDA231中MCL1的表达,分析其对细胞活力和细胞周期阶段的影响,并表征与细胞周期关键调控因子表达谱的相关性。我们进一步对745名乳腺癌患者和537名对照的-190插入多态性和邻近的单核苷酸多态性(SNP)进行了基因分型,并分析了它们与癌症风险的关系。我们证实,MCL1的表达升高导致乳腺癌细胞的增殖能力下降。我们进一步观察到,乳腺癌细胞中的MCL1过表达导致细胞周期进程停滞在S期,并伴随p27表达的增强,这可以通过p27基因敲低与小干扰RNA(siRNA)的共转染来挽救。此外,我们发现乳腺癌风险显着降低[几率(OR)?=?0.74;与-190插入基因型相关的95%置信区间(CI)?=?0.59-0.93];增强表达的调节单倍型(OR 0.79; 95%CI 0.66-0.95)和双倍型(OR 0.71; 95%CI 0.57-0.89)与癌症易感性降低相关。这项研究表明,MCL1的表达增强调控变异体是乳腺癌风险的保护性修饰因子,部分由p27介导的细胞增殖减少和细胞周期阻滞停滞可能是其潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号